| Title |
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, February 2007
|
| DOI | 10.1007/s00280-007-0423-x |
| Pubmed ID | |
| Authors |
Thomas E. Stinchcombe, Mark A. Socinski, Christine M. Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael J. Hawkins, Richard M. Goldberg, Celeste Lindley, E. Claire Dees |
| Abstract |
Albumin-bound paclitaxel, ABI-007 (Abraxane((R))), has a different toxicity profile than solvent-based paclitaxel, including a lower rate of severe neutropenia. The combination of ABI-007 and carboplatin may have significant activity in a variety of tumor types including non-small and small cell lung cancer, ovarian cancer, and breast cancer. The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Lithuania | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 46 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Master | 8 | 16% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 18% |
| Agricultural and Biological Sciences | 7 | 14% |
| Engineering | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Other | 5 | 10% |
| Unknown | 15 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2020.
All research outputs
#2,004,117
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#41
of 2,501 outputs
Outputs of similar age
#6,856
of 164,484 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 17 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.